| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-324
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57509
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-58 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-58 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate |
2005-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2009-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_853ea375703abeeaf476e23765b8243e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41b247c27d4a217e4ff56be55ff876b0 |
| publicationDate |
2009-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2311895-T3 |
| titleOfInvention |
THE USE OF BNP TYPE PEPTIDES AND ANF TYPE PEPTIDES TO ASSESS THE RISK OF PADDING A CARDIO-VASCULAR COMPLICATION AS A FREQUENCY OF OVERLOADING THE VOLUME. |
| abstract |
A method for diagnosing the risk of a patient, who does not show symptoms of a cardiovascular disease according to the NYHA classification and who has no history of cardiovascular disorder, of suffering from a cardiovascular disorder as a result of a future increase in intravascular volume, which includes stages of a) in vitro measurement of the level of a natriuretic peptide of the ANP, NT-prANP and / or BNP group, or NT-proBNP b) diagnosis of the patient's risk by comparing the level measured with at least one known level associated with the different degrees of risk in a patient. |
| priorityDate |
2004-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |